DurandML, CalderwoodSB, WeberDJ. Acute bacterial meningitis in adults: a review of 493 episodes. N Engl J Med1993; 328:21–8.
2.
RadetskyM. Duration of symptoms and outcome in bacterial meningitis: an analysis of causation and the implications of a delay in diagnosis. [Review]. Pediatr Infect Dis J1992; 11: 694–8.
3.
AroninSI, PeduzziP, QuagliarelloVJ. Community-acquired bacterial meningitis: risk stratification for adverse clinical outcome and effect of antibiotic timing. Ann Intern Med1998; 129:862–9.
4.
SchutteC-M, van der MeydenCH. A prospective study of Glasgow Coma Scale (GCS), age, CSF-neutrophil count and CSF-protein and glucose levels as prognostic indicators in 100 adult patients with meningitis. J Infect1998; 37:112–5.
5.
SchaadUB, McCrackenGH, LoockCA. Pharmacokinetics and bacteriologic efficacy of moxalactam, cefotaxime, cefoperazone and rocephin in experimental bacterial meningitis. J Infect Dis1981; 143:156–63.
6.
McCrackenGH, NelsonJD, GrimmL. Pharmacokinetics and bacteriological efficacy of cefoperazone, cefuroxime, ceftriaxone, and moxalactam in experimental Streptococcus pneumoniae and Haemophilus influenzae meningitis. Antimicrob Agents Chemother1982; 21:262–7.
7.
SchaadUB, McCrackenGH, ThrelkeldN. Clinical evaluation of a new broad-spectrum oxa-beta-lactam antibiotic, moxalactam, in neonates and infants. J Pediatr1981; 98:129–36.
8.
DecazesJM, ErnstJD, SandeMA. Correlation of in vitro time-kill curves and kinetics of bacterial killing in CSF during ceftriaxone therapy of experimental Escherichia coli meningitis. Antimicrob Agents Chemother1983; 24:463–7.
9.
TäuberMG, DoroshowCA, HackbarthCJ. Antibacterial activity of beta-lactam antibiotics in experimental meningitis due to Streptococcus pneumoniae. J Infect Dis1984; 149:568–74.
10.
ViladrichPF, GudiolF, LinaresJ. Evaluation of vancomycin for therapy of adult pneumococcal meningitis. Antimicrob Agents Chemother1991; 35:2467–72.
11.
Saez-NietoJA, LujanR, BerronS. Epidemiology and molecular basis of penicillin-resistant Neisseria meningitidis in Spain: a 5–year history (1985–1989). [Review]. Clin Infect Dis1992; 14:394–402.
12.
WoodsCR, SmithAL, WasilauskasBL. Invasive disease caused by Neisseria meningitidis relatively resistant to penicillin in North Carolina. J Infect Dis1994; 170:453–6.
13.
SutcliffeEM, JonesDM, el-SheikhS. Penicillin-insensitive meningococci in the UK. Lancet1988; 1:657–8.
14.
JonesDM, SutcliffeEM. Meningococci with reduced susceptibility to penicillin. Lancet1990; 335:863–4.
15.
LeggiadroRJ. Penicillin- and cephalosporin-resistant Streptococcus pneumoniae: an emerging microbial threat. Pediatrics1994; 93:500–3.
16.
JohnsonAP, LivermoreDM, WoodfordN. High-level β -lactam resistance in strains of Streptococcus pneumoniae isolated in the UK. J Antimicrob Chemother1998; 42:115–6.
17.
ViladrichPF, GudiolF, LinaresJ. Characteristics and antibiotic therapy of adult meningitis due to penicillin-resistant pneumococci. Am J Med1988; 84:839–46.
18.
BradleyJS, ConnorJD. Ceftriaxone failure in meningitis caused by Streptococcus pneumoniae with reduced susceptibility to beta-lactam antibiotics. Pediatr Infect Dis J1991; 10:871–3.
19.
SloasMM, BarrettFF, ChesneyPJ. Cephalosporin treatment failure in penicillin- and cephalosporin-resistant Streptococcus pneumoniae meningitis. Pediatr Infect Dis J1992; 11:662–6.
20.
FriedlandIR, KlugmanKP. Failure of chloramphenicol therapy in penicillin-resistant pneumococcal meningitis. Lancet1992; 339:405–11.
21.
FriedlandIR, McCrackenGH. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N Engl J Med1994; 331:377–82.
22.
FriedlandIR, ParisM, EhrettS. Evaluation of antimicrobial regimens for treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother1993; 37:1630–6.
23.
ParisMM, HickeySM, UscherMI. Effect of dexa-methasone on therapy of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother1994; 38:1320–4.
24.
SørensenHT, Møller-PetersenJ, KrarupHB. Early treatment of meningococcal disease. BMJ1992; 305:774.
25.
BeggN, CartwrightKAV, CohenJ. Consensus statement on diagnosis, investigation, treatment and prevention of acute bacterial meningitis in immunocompetent adults. J Infect1999; 39:1–15.
26.
QuagliarelloVJ, ScheldWM. Treatment of bacterial meningitis. N Engl J Med1997; 336(10):708–16.
27.
ViladrichPF, CabellosC, PallaresR. High doses of cefotaxime in treatment of adult meningitis due to Streptococcus pneumoniae with decreased susceptibilities to broad spectrum cephalosporins. Antimicrob Agents Chemother1996; 40: 218–20.
28.
DrydenMS, JonesNF, PhillipsI. Vancomycin therapy failure in Listeria monocytogenes peritonitis in a patient on continuous ambulatory peritoneal dialysis. J Infect Dis1991; 164:1239–40.
29.
LevitzRE, QuintilaniR. Trimethoprim-sulfamethoxazole for bacterial meningitis. Ann Intern Med1984; 100:881–90.
30.
FriedrichLV, WhiteRL, ReboliAC. Pharmacodynamics of trimethoprim-sulfamethoxazole in Listeria meningitis: a case report. Pharmacother1990; 10(4):301–4.
31.
TunkelAR, WispelweyB, ScheldWM. Bacterial meningitis: recent advances in pathophysiology and treatment. Ann Intern Med1990; 112:610–23.
32.
ScheldWM, FletcherDD, FunkFN. Response to therapy in an experimental rabbit model of meningitis due to Listeria monocytogenes. J Infect Dis1979; 140:287–94.
33.
TanTQ, SchutzeGE, MasonEO. Antibiotic therapy and acute outcome of meningitis due to Streptococcus pneumoniae considered intermediately susceptible to broad-spectrum cephalosporins. Antimicrob Agents Chemother1994; 38: 918–23.
34.
O'NeillPO. How long to treat bacterial meningitis. Lancet1993; 341:530.
